NCT06757868

Amobarbital and Cardiopulmonary Bypass

The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Detailed description

AMO is a short acting complex I blocker that blocks mitochondrial complex I between flavoprotein and ubiquitin, and its blocking effect can be rapidly reversed. Our study is to explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Conditions

• Cardiopulmonary Bypass

Interventions

Type	Name	Description
DRUG	Amobarbital	Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
DRUG	Midazolam	midazolam 0.1mg/kg is given prior to cardiopulmonary bypass

Timeline

• Start date: 2025-02-01
• Primary completion: 2025-12-31
• Completion: 2026-03-01
• First posted: 2025-01-03
• Last updated: 2025-03-21

Locations

1 site across 1 country: China